Literature DB >> 29518480

Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients.

Karen Tan1, Sai Mun Leong2, Zizheng Kee2, Patrick Vincent Caramat3, James Teo3, Michael Vito Martin Blanco4, Evelyn S C Koay2, Wai Kit Cheong5, Thomas I-Peng Soh4, Wei Peng Yong4, Angela Pang6.   

Abstract

We evaluated the changes in CTC count and CTC-associated miRNAs during the course of chemotherapy in patients with metastatic colorectal cancer. Blood samples were collected from 9 metastatic colorectal cancer patients prior to chemotherapy and at every other chemotherapy session during the course of treatment. CTCs were isolated and enumerated using a size-exclusion method (CellSievo, Singapore). CTC-associated miRNAs were isolated using a paper-based, partitioning method, and analyzed using reverse transcription quantitative real-time PCR (MiRXES, Singapore). CTC count trends generally correlated with disease progression defined by radiological measurements and trends in carcinoembryonic antigen (CEA) levels; hence CTC counts may be useful in cases where CEA is not elevated. CTC-associated miRNAs identified were miR-15b, miR-16, miR-19a, miR-21, miR-25, miR-30d, miR-126, miR-185, miR-221, miR-222, and miR-324-5p. The expression of CTC-associated miRNAs did not appear to correlate with CTC count and exhibited inter-individual heterogeneity. This pilot study suggests that analysis of CTC changes during the course of treatment may be useful in monitoring response to therapy in metastatic colorectal cancer.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Chemotherapy; Circulating tumor cells; Metastatic colorectal cancer; microRNA

Mesh:

Substances:

Year:  2018        PMID: 29518480     DOI: 10.1016/j.canlet.2018.02.039

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Optimal adjuvant chemotherapy completion time for stage III colon cancer: a cohort study.

Authors:  Jing-Qing Ren; Han-Shuo Zhang; Li-Hua Zhang; Qi-Guang Zhong; Fan Wu; Bai-Lin Wang; Shao-Jie Liu
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  Combined Features Based on Preoperative Controlling Nutritional Status Score and Circulating Tumour Cell Status Predict Prognosis for Colorectal Cancer Patients Treated with Curative Resection.

Authors:  Chaogang Yang; Chen Wei; Shuyi Wang; Song Han; Dongdong Shi; Chunxiao Zhang; Xiaobin Lin; Rongzhang Dou; Bin Xiong
Journal:  Int J Biol Sci       Date:  2019-05-12       Impact factor: 6.580

Review 3.  Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity.

Authors:  Marta Tellez-Gabriel; Marie-Françoise Heymann; Dominique Heymann
Journal:  Theranostics       Date:  2019-06-19       Impact factor: 11.556

4.  Isolation and Enumeration of CTC in Colorectal Cancer Patients: Introduction of a Novel Cell Imaging Approach and Comparison to Cellular and Molecular Detection Techniques.

Authors:  Alexander Hendricks; Burkhard Brandt; Reinhild Geisen; Katharina Dall; Christian Röder; Clemens Schafmayer; Thomas Becker; Sebastian Hinz; Susanne Sebens
Journal:  Cancers (Basel)       Date:  2020-09-16       Impact factor: 6.639

5.  Portal Venous Circulating Tumor Cells Undergoing Epithelial-Mesenchymal Transition Exhibit Distinct Clinical Significance in Pancreatic Ductal Adenocarcinoma.

Authors:  Yujin Pan; Deyu Li; Jiuhui Yang; Ning Wang; Erwei Xiao; Lianyuan Tao; Xiangming Ding; Peichun Sun; Dongxiao Li
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244

6.  Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.

Authors:  Mio Ikeda; Yasuhiro Koh; Shunsuke Teraoka; Koichi Sato; Jun Oyanagi; Atsushi Hayata; Nahomi Tokudome; Hiroaki Akamatsu; Yuichi Ozawa; Katsuya Endo; Masayuki Higuchi; Masanori Nakanishi; Hiroki Ueda; Nobuyuki Yamamoto
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

7.  The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer.

Authors:  Jian Zheng; Xiong Ye; Yanan Liu; Yuxia Zhao; Mudan He; Hui Xiao
Journal:  BMC Cancer       Date:  2020-02-10       Impact factor: 4.430

8.  Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Authors:  P García-Alfonso; R García-Carbonero; J García-Foncillas; P Pérez-Segura; R Salazar; R Vera; S Ramón Y Cajal; J Hernández-Losa; S Landolfi; E Musulén; M Cuatrecasas; S Navarro
Journal:  Clin Transl Oncol       Date:  2020-05-16       Impact factor: 3.405

9.  Utility of circulating tumor cells in stage II colorectal cancer patients undergoing curative resection.

Authors:  Jun-Hui Yu; Dong Wang; Lan Jin; Jin Wang; Xiao-Mu Zhao; Guo-Cong Wu; Hong-Wei Yao; Ying-Chi Yang; Zhong-Tao Zhang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

10.  Longitudinal Analysis of Circulating Tumor Cells in Colorectal Cancer Patients by a Cytological and Molecular Approach: Feasibility and Clinical Application.

Authors:  Alexander Hendricks; Katharina Dall; Burkhard Brandt; Reinhild Geisen; Christian Röder; Clemens Schafmayer; Thomas Becker; Sebastian Hinz; Susanne Sebens
Journal:  Front Oncol       Date:  2021-06-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.